Peripheral Arterial Disease Clinical Trial
— FIRESTEPOfficial title:
Flexion-Induced Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
Verified date | March 2024 |
Source | Kantonsspital Aarau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The femoro-popliteal (FP) artery is the most frequently treated vascular segment in patients with symptomatic peripheral artery disease (PAD), for which endovascular therapy became an established treatment option during the last decades. However, loss of primary patency and consecutive clinically driven target lesion revascularization (TLR) limit this procedure. Moreover, in the popliteal artery (PA), evidence about the best treatment strategy to prevent loss of patency and TLR is limited to only a few randomized controlled trials (RCT). Arterial deformations of the PA with its unique anatomical properties during leg flexion might explain the poor technical and clinical outcomes in this segment. Generally, a "leave nothing behind" strategy in the PA is preferred, but cannot be avoided in all cases due to e.g. flow limiting dissections or re-coil after balloon angioplasty. Basically two different self-expandable nitinol-based stent designs are available on the market. An interwoven nitinol and laser-cut nitinol stent. The interwoven nitinol stent has a higher radial force in comparison to the laser-cut stent and reveals higher patency rates in the FP arteries. However, a head-to-head comparison of these stents is missing and it remains unknown in which way different stent designs affect the deformation and hemodynamic behaviors of the PA during knee flexion.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 1, 2024 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 85 Years |
Eligibility | Inclusion Criteria: - Written informed consent prior to any study procedure, - Presence of PAD (2 - 3 Rutherford-Becker class), - Atherosclerotic de-novo lesion (stenosis >70% or occlusion) of the distal part of the superficial femoral artery and/or any part of the popliteal artery, - Target lesion-length: 4cm to 12cm, - Target vessel diameter: 5mm to 7mm, - Guidewire must cross target lesion and located intraluminally before randomization, - At least one (1) patent below-the knee artery (=with no stenosis >50%), - Possibility to treat the target lesion with one (1) study stent - Interventions in TASC A and B lesions to restore adequate blood flow, in the same index procedure, are allowed. This intervention must be prior to the treatment of the study lesion(s) and successful. Exclusion Criteria: - Pregnancy, - Angiographic evidence of thrombus within the target lesion, - Patients with acute critical limb ischemia (Rutherford-Becker class 4-6), - Restenosis of the target lesion, - Non-atherosclerotic obstructions of the target lesion, - Aneurysm of the target lesion, - Renal failure, defined as GFR, <40 mL/min/1.73m2, - Patient's inability to follow the study procedures e.g. psychological disorders, dementia, etc., - Previous enrolment into an ongoing study, - Known or suspected allergies or contraindications to aspirin and/or clopidogrel, heparin, - Coagulation disorders, or general refusal of the patient to receive blood transfusions, - Contrast allergy that cannot be treated, - Thrombolysis therapy including 72 hours before the planned index procedure, - Myocardial infarction or stroke <30 days prior to index procedure. - Equipment is unavailable to fulfill study treatments. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kantonsspital Aarau |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary patency | Primary patency of the target lesion measured by duplex ultrasound | 1 year post index procedure | |
Secondary | Changes in arterial flow within the target lesion | Changes in blood flow/hemodynamics caused by the different stent designs measured by Computational Fluid Dynamics | 6 weeks, 6 months, and 1 year post index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |